Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial

被引:73
|
作者
Azizi, Fereidoun [1 ]
Amouzegar, Atieh [1 ]
Tohidi, Maryam [2 ]
Hedayati, Mehdi [3 ]
Khalili, Davood [2 ,4 ]
Cheraghi, Leila [4 ]
Mehrabi, Yadollah [5 ]
Takyar, Miralireza [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, POB 19395-4763, Tehran 1985717413, Iran
[2] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Prevent Metab Disorders Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Cellular & Mol Endocrine Res Ctr, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Dept Epidemiol & Biostat, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Epidemiol & Biostat, Tehran, Iran
关键词
long-term; methimazole; Graves' disease; remission rates; ANTITHYROID DRUG-TREATMENT; HYPERTHYROIDISM; EXPOSURE; IODINE; RISK;
D O I
10.1089/thy.2019.0180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length methimazole therapy. We also sought variables associated with relapse following the latter. Methods: We enrolled 302 consecutive patients with untreated first episodes of Graves' hyperthyroidism. After 18-24 months of methimazole, 258 patients (85.4%) were randomized to an additional 36-102-month courses ("long-term group": n = 130; scheduled total time on methimazole: 60-120 months) or discontinuation of methimazole ("conventional group": n = 128). Patients were followed 48 months postmethimazole cessation. We performed Cox proportional hazards modeling to identify factors associated with relapse after conventional courses. Results: Methimazole was given for 95 +/- 22 months in long-term patients and 19 +/- 3 months in the conventional group. Fourteen patients experienced cutaneous reactions and 2 liver enzyme elevations during the first 18 months of treatment; no further methimazole-related reactions were observed despite therapy for up to another 118 months. Hyperthyroidism recurred within 48 months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877 CD28 polymorphism or the DQB1-05 HLA polymorphism were independently associated with relapse. Conclusion: Administration of low-dose methimazole for a total of 60-120 months safely and effectively treats Graves' hyperthyroidism, with much higher remission rates than those attained by using conventional 18-24-month courses.
引用
收藏
页码:1192 / 1200
页数:9
相关论文
共 50 条
  • [31] Remission Rate in the Patients with Graves' Disease after Treatment with a Minimum Maintenance Dose of Methimazole for 12 Months
    Mutsuo, Beniko
    Hiroyuki, Ikawa
    Takayuki, Mori
    Yasuo, Mashio
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [32] Benefits of Long-Term Continuation of Low-Dose Methimazole Therapy in the Prevention of Recurrent Hyperthyroidism in Graves' Hyperthyroid Patients: A Randomized Prospective Controlled Study
    Lertwattanarak, Raweewan
    Kunavisarut, Tada
    Sriussadaporn, Sutin
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2022, 2022
  • [33] PREDICTORS OF DISEASE COURSE AFTER THE DISCONTINUATION OF BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS PATIENTS WITH LONG-TERM REMISSION
    Kadar, G.
    Czibula, A.
    Szalay, B.
    Nagy, K.
    Pusztai, A.
    Balog, A.
    Monostori, E.
    Vasarhelyi, B.
    Szekanecz, Z.
    Kovacs, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1007 - 1007
  • [34] LOW REMISSION AFTER LONG-TERM ANTITHYROID TREATMENT OF GRAVES-DISEASE IN RELATION TO IODINE INTAKE
    SIERSBAEKNIELSEN, K
    FRIIS, T
    LUMHOLTZ, B
    POULSEN, D
    ROGOWSKI, P
    MOLHOLMHANSEN, J
    ACTA ENDOCRINOLOGICA, 1975, 80 : 170 - 170
  • [35] Long-term results of antireflux surgery indicate the need for a randomized clinical trial
    Sandbu, R
    Khamis, H
    Gustavsson, S
    Haglund, U
    BRITISH JOURNAL OF SURGERY, 2002, 89 (02) : 225 - 230
  • [36] The Differential Effects of Propylthiouracil and Methimazole as Graves' Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
    Wisnu, Wismandari
    Alwi, Idrus
    Nafrialdi, Nafrialdi
    Harimurti, Kuntjoro
    Pemayun, Tjokorda Gede D.
    Jusman, Sri Widia A.
    Santoso, Dewi Irawati S.
    Harahap, Alida R.
    Suwarto, Suhendro
    Subekti, Imam
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [37] Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease
    van den Bosch, O. F. C.
    Stades, A. M. E.
    Zelissen, P. M. J.
    CLINICAL ENDOCRINOLOGY, 2014, 80 (02) : 184 - 190
  • [38] CONTROLLED CLINICAL TRIAL OF LONG-TERM ANTICOAGULANT THERAPY IN CEREBROVASCULAR DISEASE
    HILL, AB
    MARSHALL, J
    SHAW, DA
    QUARTERLY JOURNAL OF MEDICINE, 1960, 29 (116): : 597 - 609
  • [39] T3 RELEASE STIMULATING ANTIBODIES IN PATIENTS WITH LONG-TERM REMISSION OF GRAVES-DISEASE
    HORMANN, R
    HOBELSBERGER, A
    SALLER, B
    ACTA ENDOCRINOLOGICA, 1986, 111 : 53 - 53
  • [40] Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience
    Bayramoglu, Elvan
    Elmaogullari, Selin
    Sagsak, Elif
    Aycan, Zehra
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2019, 32 (04): : 341 - 346